Gerhard Gmaschitz

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo

Christiane Kofink, Nicole Trainor, Barbara Mair et al. · Nature Communications · 2022 · 206 citations · Full text

Medicine, Molecular Biology, Oncology +15

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS ^G12C Inhibitor

Joachim Bröker, Alex G. Waterson, Chris A. Smethurst et al. · Journal of Medicinal Chemistry · 2022 · 81 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria

Lukas Junk, Volker M. Schmiedel, Somraj Guha et al. · Nature Communications · 2024 · 47 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +15

Targeted Synthesis of Complex Spiro[3<i>H</i>‐indole‐3,2′‐pyrrolidin]‐2(1<i>H</i>)‐ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2–p53 Inhibitors

Andreas Gollner, Harald Weinstabl, Julian E. Fuchs et al. · ChemMedChem · 2018 · 28 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo

Christiane Kofink, Nicole Trainor, Barbara Mair et al. · ChemRxiv · 2022 · 21 citations · Full text

Medicine, Molecular Biology, Oncology +15